Skip to main content

Table 1 The tumor response and median PFS of phase II HCC trials on bevacizumab, 2006-2012

From: Mixed response and time-to-event endpoints for multistage single-arm phase II design

Article

Treatment arms

Median TTP/PFS (Month)

Response rate (%)

Zhu et al., 2006 [22]

GEMOX + Bevacizumab

5.3

20

Siegel et al., 2008 [23]

Bevacizumab

6.9

13.04

Thomas et al., 2009 [24]

Bevacizumab + Erlotinib

9.0

25

Hsu et al., 2010 [22]

Bevacizumab + Capecitabine

2.7

8.89

Sun et al., 2011 [26]

Bevacizumab + Capecitabine + Oxaliplatin

6.8

20

Kaseb et al., 2012 [27]

Bevacizumab + Erlotinib

7.2

23.73

Philip et al., 2012 [28]

Bevacizumab + Erlotinib

3.0

3.7

Yau et al., 2012 [29]

Bevacizumab + Erlotinib

1.5

0